US 7,622,249 B2Granted

Method for diagnosing and/or predicting of a septic syndrome

AssigneeBiomerieux

InventorAlexandre Pachot

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention relates to a method for diagnosing and/or predicting a septic syndrome, wherein: a. a biological sample from the patient is made available and biological material is extracted from the biological sample b. at least four specific reagents which are selected from the following specific reagents are made available: reagent which is specific for the target gene IL-10, reagent which is specific for the target gene TGFβ, reagent which is specific for the target gene HMG1, reagent which is specific for the target gene T-bet, reagent which is specific for the target gene IL-1β, reagent which is specific for the target gene TNFα and reagent which is specific for the target gene GATA-3 c. the expression of at least four target genes selected from: IL-10, TGFβ, HMG1, T-bet, IL-1β, TNFα and GATA-3 is determined. The present invention also relates to a kit for diagnosing and/or predicting a septic syndrome.

Claims4

Dependent claims

A method for diagnosing and/or predicting a septic syndrome, the method comprising:

a. obtaining a blood sample from a patient;
b. extracting biological material from the blood sample;
c. contacting the biological material with:
a reagent for demonstrating expression of IL-10 gene,
a reagent for demonstrating expression of TGFβ gene,
a reagent for demonstrating expression of HMG1 gene,
a reagent for demonstrating expression of IL-1β gene;
and
a reagent for demonstrating expression of T-bet gene;
d. determining the expression levels of the IL-10 gene, TGFβ gene, the HMG1 gene, the IL-1β gene and the T-bet gene in said blood sample;
and
e. comparing the expression levels of the IL-10 gene, the TGFβ gene, the HMG1 gene, the IL-1β gene and T-bet gene in said blood sample to known control mean expression values of each of the genes in order to diagnose and/or predict a septic syndrome based on a variation in the expression of each gene in the blood sample when compared to the corresponding known control mean expression value.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/559,292Filed 2 Jun 2004
Priority: FR 03 066603 Jun 2003
Published: US 2006/0127912 A115 Jun 2006
Granted: 24 Nov 2009
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/118
Oligonucleotides characterized by their use: prognosis of disease development
C12Q 2600/158
Oligonucleotides characterized by their use: expression markers
C12Q
Measuring or testing processes involving enzymes, nucleic acids or microorganisms